middle.news
Biotron Advances SedRx Regulatory Pathway and Broadens Antiviral Scope with $878K Raise
10:32am on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
Biotron Advances SedRx Regulatory Pathway and Broadens Antiviral Scope with $878K Raise
10:32am on Wednesday 29th of April, 2026 AEST
Key Points
Sedarex fully integrated into Biotron operations
EMA submission preparations for SedRx progressing
BIT-HBV001 shows ~85% inhibition of HDV markers
Rights issue shortfall raises $878,000
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE